一分钟看懂
这是一项关于非小细胞肺癌的II 期研究，登记的药物或干预包括BMS-986504；Izalontamab Brengitecan，当前状态为招募中。登记地点显示中国北京、厦门、南宁、南昌等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
BMS-986504；Izalontamab Brengitecan · II 期
登记条件中文摘要
登记的基本范围为不限性别，年龄18 岁；另列出8项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出7项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Beijing Chest Hospital,Capital Medical University · 北京
- The First Affiliated hospital of Xiamen University · 厦门
- Guangxi Medical University Affiliated Tumor Hospital · 南宁
- The First Affiliated Hospital of Nanchang University · 南昌
- Shandong Cancer Hospital · 济南
- LinYi Cancer Hospital · 临沂
- Sir Run Run Shaw Hospital of Zhejiang University School of Medicine · 杭州
- Taizhou Hospital of Zhejiang Province · 临海
公开的入选条件
- * Histologically confirmed diagnosis of NSCLC and homozygous MTAP deletion detected in tumor tissue and willingness to provide archival/fresh samples at screening for central MTAP status confirmation.
- * Advanced or metastatic NSCLC not amenable to curative therapies after progression on prior therapies at the time of enrollment (based on the American Joint Committee on Cancer, Ninth Edition).
- * At least 1 measurable lesion as per RECIST v1.1.
- * Documented radiographic disease progression on or after the most recent line of treatment.
- * Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
- * Participant must be ≥ 18 years of age (or the legal age of consent in the jurisdiction in which the study is taking place) at the time of signing the ICF.
- * Capability to swallow tablets intact (without chewing or crushing).
- * For combination arms
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06855771；登记信息更新于 2026-09-18。